ADGRB3 and cancer: GPR56 was reported by us and other to be downregulated during melanoma malignancy in humans, and the adhesion GPCRs LPN3 and BAI3 were found frequently mutated in human cancer samples, further strengthening the clinical relevance of these receptors on cancer progression (67).